NU-SUMATRIPTAN 100 MG
SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 100 MG · DIN 02336065 · NU-PHARM INC
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is NU-SUMATRIPTAN?
NU-SUMATRIPTAN 100 MG contains SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02336065, held by NU-PHARM INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 28-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NU-SUMATRIPTAN used for?
Acute treatment of migraine attacks with or without aura in adults. Not for prophylactic therapy or management of hemiplegic, basilar, or ophthalmoplegic migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02336065 |
|---|---|
| Brand name | NU-SUMATRIPTAN |
| Generic / active ingredient | SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 100 MG |
| Manufacturer | NU-PHARM INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC01 SUMATRIPTAN |
| AHFS class | 28:32.28 |
| Biosimilar | No |
| Health Canada status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 28-Mar-2018 |
How is it administered?
Acute treatment: 25 mg, 50 mg, or 100 mg. If symptoms recur, a second dose may be taken after 2 hours. Maximum daily dose is 200 mg. Hepatic impairment: consider 25 mg dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; uncontrolled hypertension; use of MAO inhibitors within 2 weeks; use of ergot-containing drugs within 24 hours; severe hepatic impairment.
Warnings and precautions
Risk of myocardial ischemia/infarction; sumatriptan may cause coronary vasospasm. Potential for significant blood pressure elevation. Caution in patients with history of seizures.
Is SUMATRIPTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02CC01 SUMATRIPTAN. 32 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUMATRIPTAN | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02268396 |
| APO-SUMATRIPTAN | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02268388 |
| IMITREX | 20 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230420 |
| IMITREX | 5 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230418 |
| IMITREX | 6 MG / 0.5 ML | SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02212188 |
| IMITREX DF - TAB 100MG | 100 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02212161 |
| JAMP SUMATRIPTAN | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545365 |
| JAMP SUMATRIPTAN | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545349 |
| JAMP SUMATRIPTAN | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545357 |
| JAMP SUMATRIPTAN DF | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545314 |
Who else supplies SUMATRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUMATRIPTAN appears in 269 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.